Suppr超能文献

新型冠状病毒抗体阳性多发性硬化症患者中疾病修正治疗的安全性。

Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.

机构信息

Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.

Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.

出版信息

Mult Scler Relat Disord. 2021 Apr;49:102754. doi: 10.1016/j.msard.2021.102754. Epub 2021 Jan 13.

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs that inhibit immune cell trafficking, such as natalizumab (NTZ) and fingolimod (FTY), remains to be determined, as do the possible effects of these drugs on both the infection and the related disease.

AIMS

To describe self-reported COVID-19 symptoms and disease severity in PwMS on NTZ or FTY who received serology confirmation of SARS-CoV-2 infection.

METHODS

From 27th April to 3rd May 2020, telephone interviews were conducted with 140 PwMS under treatment with NTZ or FTY in order to collect structured data on multiple sclerosis (MS) and COVID-19. The patients, all followed at our center, were classified as symptomatic, paucisymptomatic or asymptomatic on the basis of their self-reported clinical characteristics. COVID-19 severity was rated on a 7-point ordinal scale. In addition, in the period 4th May to 3rd June 2020 SARS-CoV-2 serology testing, using the Roche SARS-CoV-2 IgG assay (Elecsys), was performed in 104/140 (74.2%) of the interviewed PwMS (50 treated with NTZ and 54 with FTY).

RESULTS

14/104 (13.4%) PwMS on NTZ or FTY had anti-SARS-CoV-2 antibodies: 8 met the criteria for asymptomatic, 3 for paucisymptomatic and 3 for symptomatic COVID-19 (COVID-19 severity score lower than 3). None of them required hospitalization or showed severe COVID-19 complications.

CONCLUSIONS

Despite the relatively high SARS CoV-2 seroprevalence found in this sample of PwMS, all the positive cases showed either no or only mild COVID-19 symptoms. These reassuring findings indicate a lack of COVID-19 complications in PwMS on DMTs and support the hypothesis that it is safe to maintain ongoing treatment with these drugs in the current setting.

摘要

背景

新型冠状病毒病 2019(COVID-19)对接受疾病修正治疗(DMT)的多发性硬化症(PwMS)患者和为其治疗的医生来说是一个特别关注的问题。严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染对接受抑制免疫细胞迁移的 DMT 治疗的 PwMS 的影响,如那他珠单抗(NTZ)和 fingolimod(FTY),仍有待确定,这些药物对感染和相关疾病的可能影响也是如此。

目的

描述接受 SARS-CoV-2 感染血清学确认的接受 NTZ 或 FTY 治疗的 PwMS 中自我报告的 COVID-19 症状和疾病严重程度。

方法

2020 年 4 月 27 日至 5 月 3 日,对 140 名在我们中心接受 NTZ 或 FTY 治疗的 PwMS 进行了电话访谈,以收集多发性硬化症(MS)和 COVID-19 的多项数据。根据自我报告的临床特征,这些患者均被归类为有症状、症状轻微或无症状。COVID-19 严重程度按 7 分等级评定。此外,在 2020 年 5 月 4 日至 6 月 3 日期间,对 140 名接受访谈的 PwMS 中的 104 名(NTZ 治疗 50 名,FTY 治疗 54 名)进行了罗氏 SARS-CoV-2 IgG 检测(Elecsys)的 SARS-CoV-2 血清学检测。

结果

104 名接受 NTZ 或 FTY 治疗的 PwMS 中有 14 名(13.4%)具有抗 SARS-CoV-2 抗体:8 名符合无症状标准,3 名符合症状轻微标准,3 名符合有症状 COVID-19(COVID-19 严重程度评分低于 3)。他们都不需要住院治疗,也没有出现严重的 COVID-19 并发症。

结论

尽管在该 PwMS 样本中发现 SARS CoV-2 血清阳性率较高,但所有阳性病例均表现为无或仅有轻微 COVID-19 症状。这些令人安心的发现表明 DMT 治疗的 PwMS 中 COVID-19 并发症并不常见,支持了在当前情况下继续使用这些药物进行治疗是安全的假设。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d3c/7836789/395d71a7b6d3/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验